<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, we and others could define the molecular cause of the <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> congenital <z:hpo ids='HP_0004859'>amegakaryocytic thrombocytopenia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAMT</z:e>) as mutations in the c-mpl gene (Blood 97: 139, 2001) </plain></SENT>
<SENT sid="1" pm="."><plain>We proposed that c-mpl mutations are the cause not only for the hypomegakaryocytic <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, but also for the development of an <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAMT</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The effects of thrombopoietin (TPO) on early multipotent hematopoietic progenitors were elucidated by a recent series of in vitro and in vivo studies </plain></SENT>
<SENT sid="3" pm="."><plain>Like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAMT</z:e> patients, mice lacking the TPO receptor c-Mpl demonstrate a major reduction of early hematopoietic progenitor cells of <z:hpo ids='HP_0000001'>all</z:hpo> lineages </plain></SENT>
<SENT sid="4" pm="."><plain>However, these mice achieve a <z:mpath ids='MPATH_458'>normal</z:mpath> marrow cellularity and composition, despite the lack of megakaryocytes </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, the incidence of development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAMT</z:e> is not clear owing to difficult and not consistent diagnosis of this disease </plain></SENT>
</text></document>